Goldman Sachs’s Cardiff Oncology CRDF Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $157K | Sell |
120,827
-14,771
| -11% | -$23.5K | ﹤0.01% | 6259 |
|
|
2026
Q1 | $220K | Sell |
135,598
-249,488
| -65% | -$512K | ﹤0.01% | 6041 |
|
|
2025
Q4 | $1.08M | Sell |
385,086
-69,640
| -15% | -$162K | ﹤0.01% | 5083 |
|
|
2025
Q3 | $937K | Buy |
454,726
+378,392
| +496% | +$1.05M | ﹤0.01% | 5071 |
|
|
2025
Q2 | $240K | Sell |
76,334
-30,799
| -29% | -$93.9K | ﹤0.01% | 5567 |
|
|
2025
Q1 | $336K | Sell |
107,133
-45,901
| -30% | -$182K | ﹤0.01% | 5405 |
|
|
2024
Q4 | $664K | Buy |
153,034
+59,053
| +63% | +$185K | ﹤0.01% | 5076 |
|
|
2024
Q3 | $251K | Sell |
93,981
-58,881
| -39% | -$139K | ﹤0.01% | 5376 |
|
|
2024
Q2 | $339K | Sell |
152,862
-133,012
| -47% | -$501K | ﹤0.01% | 5030 |
|
|
2024
Q1 | $1.53M | Buy |
+285,874
| New | +$760K | ﹤0.01% | 4060 |
|
|
2022
Q4 | – | Sell |
-14,349
| Closed | -$22K | – | 6016 |
|
|
2022
Q3 | $22K | Sell |
14,349
-27,503
| -66% | -$66.2K | ﹤0.01% | 5916 |
|
|
2022
Q2 | $92K | Sell |
41,852
-305,195
| -88% | -$511K | ﹤0.01% | 5884 |
|
|
2022
Q1 | $861K | Sell |
347,047
-23,081
| -6% | -$81.6K | ﹤0.01% | 4942 |
|
|
2021
Q4 | $2.22M | Buy |
370,128
+12,456
| +3% | +$74.2K | ﹤0.01% | 4168 |
|
|
2021
Q3 | $2.38M | Buy |
357,672
+275,151
| +333% | +$1.73M | ﹤0.01% | 4027 |
|
|
2021
Q2 | $549K | Buy |
82,521
+19,144
| +30% | +$162K | ﹤0.01% | 5158 |
|
|
2021
Q1 | $587K | Buy |
+63,377
| New | +$770K | ﹤0.01% | 4998 |
|
|
2018
Q2 | – | Sell |
-209
| Closed | -$5K | – | 5708 |
|
|
2018
Q1 | $5K | Sell |
209
-4
| -2% | -$99 | ﹤0.01% | 5802 |
|
|
2017
Q4 | $5K | Buy |
213
+6
| +3% | +$266 | ﹤0.01% | 6248 |
|
|
2017
Q3 | $11K | Sell |
207
-3,657
| -95% | -$228K | ﹤0.01% | 6521 |
|
|
2017
Q2 | $351K | Buy |
3,864
+3,536
| +1,078% | +$228K | ﹤0.01% | 5372 |
|
|
2017
Q1 | $27K | Sell |
328
-313
| -49% | -$42.5K | ﹤0.01% | 6441 |
|
|
2016
Q4 | $97K | Sell |
641
-1,015
| -61% | -$237K | ﹤0.01% | 6158 |
|
|
2016
Q3 | $535K | Sell |
1,656
-1,031
| -38% | -$376K | ﹤0.01% | 4976 |
|
|
2016
Q2 | $876K | Sell |
2,687
-278
| -9% | -$95.8K | ﹤0.01% | 4311 |
|
|
2016
Q1 | $993K | Buy |
2,965
+767
| +35% | +$261K | ﹤0.01% | 4081 |
|
|
2015
Q4 | $855K | Buy |
2,198
+159
| +8% | +$62.3K | ﹤0.01% | 4453 |
|
|
2015
Q3 | $835K | Sell |
2,039
-2,256
| -53% | -$1.18M | ﹤0.01% | 4651 |
|
|
2015
Q2 | $3.14M | Buy |
+4,295
| New | +$3.05M | ﹤0.01% | 3391 |
|
Other funds holding CRDF
LCM
P
Goldman Sachs's CRDF Position: Q2 2026 in Review
Goldman Sachs reduced its Cardiff Oncology (CRDF) stake by 11% in Q2 2026, selling an estimated $23.5K and leaving 120,827 shares worth $157K. The position accounts for ﹤0.01% of the portfolio, ranked #6259.
Goldman Sachs first reported a position in CRDF in Q2 2015 and has held it in 29 quarters since. The position peaked at $3.14M in Q2 2015. 104 funds tracked by Wall St. Rank hold CRDF as of Q2 2026.
- Goldman Sachs held 120,827 shares of Cardiff Oncology worth $157K as of Q2 2026.
- Goldman Sachs sold 14,771 Cardiff Oncology shares in Q2 2026, an estimated $23.5K.
- Cardiff Oncology made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #6259 holding.
- Goldman Sachs first reported a position in Cardiff Oncology in Q2 2015 and has held it in 29 quarters since.
- Goldman Sachs's Cardiff Oncology position peaked at $3.14M in Q2 2015.
- 104 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2026.
Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.